Author | Ricki Lewis, PhD


Cell Phones vs Brain Tumors: Can You Hear Me Now?

April 04, 2006


brain tumor, neuroma, tumorigenesis, cell phone use

Antidepressants: The Risk/Benefit Saga Continues

April 02, 2006


Selective serotonin reuptake inhibitors, SSRIs, Suicidality, Depression, Major depressive disorder, Neonatal abstinence syndrome

Neural Enhancement: A Slippery Slope for Neurologists

March 31, 2006


cognitive enhancement, cosmetic neurology

Huntington Disease: The Orphan Enigma

December 01, 2005


Huntington disease, neurogenetics, George Sumner Huntington, Systematic Evaluation of Treatments for Huntington's Disease, Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis

The Continuing Saga of GDNF and Parkinson Disease

August 01, 2005



"Stubborn Optimism" Dominates the Landscape of ALS

July 01, 2005


Animal models enable researchers to track amyotrophic lateral sclerosis (ALS) pathogenesis. Erik Storkebaum, MSc, and colleagues at the Center for Transgene Technology and Gene Therapy at Flanders Interuniversity, Leuven, Belgium, took several approaches to increase supply of the neuroprotective protein vascular endothelial growth factor (VEGF) in an animal model. "When administered to rats at 60 days, which is 1 month before symptoms, it delayed onset and prolonged survival by 22 days. When we gave VEGF at the age of disease onset, which more closely mimics the human situation, the treatment still prolonged life by an average of 10 days," Storkebaum reported at the Society for Neuroscience annual meeting in October 2004

Parkinson Disease: The Ups and Downs of Developing Therapies

April 09, 2005


Levodopa (l-dopa) and dopamine agonists are the main treatment for Parkinson disease (PD), but these therapies are of limited value in the long course of the illness because they counter a neurotransmitter deficit but do not halt neurodegeneration. In this main article and in an accompanying story, we offer an update on the status of Parkinson treatments today.

US Stem Cell Research Gets Boost as Neurologists Await Therapies

January 22, 2005


Early applications ofstem cell medicine arelikely to be neurologic,targeting spinal cord injury,brain tumors, metabolic derangements,and disordersof movement and mood. Althoughtreatments are stillyears away, continual mediacoverage of the fledglingtechnology is fueling questionsin the doctor’s office.“For our patients with devastatingneurological conditions,stem cell researchgives them hope of newtherapeutic measures,” saidSandra Olson, MD, presidentof the American Academyof Neurology (AAN).